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Gastrointestinal stromal tumor (GIST), the most common sarcoma arising in the gastrointestinal tract, typically expresses the tyrosine-kinase
receptor, C-KIT, and contains activating mutation in the c-kit or platelet-derived growth factor receptor (pdgfr) gene. Recently, development
of small molecules that inhibit the kinase activity of mutant C-KIT and PDGFR proteins has radically changed treatment and prognosis of
patients diagnosed with advanced GIST as this molecularly ‘‘targeted’’ therapy has demonstrated remarkable high-level of activity in this disease.
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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) have emerged as a dis-
tinct entity over the past few decades as tumor identiﬁcation has
improved and GISTs are now being readily identiﬁed by speciﬁc
immunohistochemistry. As noted in the National Comprehensive
Cancer Network (NCCN) Task Force Report, the world-wide inci-
dence of GIST is thought to be approximately 10 cases per million
persons each year; an incidence estimated based on reported annual
incidence ranging between 6.5 and 14.5 cases per million [1]. Many
advances in the treatment of GISTs have emerged over the past dec-
ade following the recognition of this distinct entity with the greatest
impact on management of advanced or metastatic disease achieved
by the introduction of imatinib and other tyrosine kinase inhibitors.
Before imatinib, the median survival of patients diagnosed with
advanced GIST was 10–17 months [2]. In this day and age, patients
with advanced disease treated with tyrosine kinase inhibitors are now
living >50 months [3]. This review will help to clarify some of the
latest advances and the current standard of care for treating advanced
GIST in this era.
GISTs are malignant tumors that have been found to arise in all
areas of the gastrointestinal tract from the esophagus to the rectum
and may originate from the pacemaker cells of the GI tract, the inter-
stitial cells of Cajal. The most common site of origin is the stomach
(60%), followed by small intestine (30%), duodenum (5%), colon/
rectum (<5%), and esophagus (<1%) [1]. GISTs can rarely originate
in the omentum, mesentery, or retroperitoneum; extra-gastrointestinal
GISTs seem to behave in an aggressive way, similar to small bowel
GISTs [4]. GISTs have the potential to metastasize to distant sites,
but usually spread locally to peritoneal surfaces, the omentum and to
liver. GISTs rarely metastasize to the lung unlike other sarcomas [5].
Lymph node and bone involvement, and spread outside of the
abdominal cavity are exceedingly uncommon compared to GIST pro-
pensity for local spread [6]. Great care must be undertaken
when excising GISTs as these tumors also have the potential to seed
areas in the abdomen following peri-operative tumor rupture. Tumor
seeding during needle biopsy to establish the diagnosis may also
occur [1].
Prior to describing the treatment of advanced GIST, it is prudent
to ﬁrst review some of the pathophysiology of the disease since
many of the drug treatments interact with proteins important in
the genesis of GIST. Certain mutations that activate speciﬁc
proteins have been found to be involved in GIST pathogenesis.
These activated proteins are now targets for effective therapies in
GIST treatment. Approximately 90% of GISTs have activating
mutations in genes for the transmembrane receptors C-KIT or plate-
let derived growth factor receptor-alpha (PDGFR-A) [7]. The
majority of GISTs (85%) contain activating mutations in c-kit, 5%
contain mutations in pdgfr-a, and the remainder of GISTs do not
contain identiﬁable mutations in either of these two receptor kinases,
otherwise known as ‘‘wild-type’’ GIST. Mutations in exon 11 of
c-kit are the most common and convey a high degree of sensitivity to
ﬁrst-line therapy with imatinib, which will be discussed in greater
detail later in this review [1]. Exon 9 c-kit mutations are the second
most common mutations in this transmembrane receptor and are
associated with a different sensitivitiy to imatinib and to other tyro-
sine kinase inhibitors. Mutations in exons 13, 14, 17, and 18 of c-kit
have also been described, though less commonly, and in some
cases have been associated with primary or secondary resistance to
imatinib. Mutations in exons 12, 14, and 18 in pdgfr-a have been
found to be the etiology for many GISTs that do not have activating
mutations in c-kit and carry with them their own prognosis based on
responsiveness to drugs currently available [8]. Some wild-type
GISTs without mutations in c-kit or pdgfr-a have increased expres-
sion of insulin-like growth factor-1 receptor (IGF1-R) [9] and a
potentially worse prognosis as this phenotype is associated with a
higher mitotic index, larger size, and higher rate of recurrence and
metastasis [10].
Patients with certain genetic disorders such as von Recklinghau-
sen’s disease, familial GIST, and Carney-Stratakis syndrome make
up a small percentage of the GIST population. Another disorder,
Carney’s triad, is a non-inherited condition that has been described
in less than 100 GIST patients world-wide, and is associated with
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extra-adrenal paragangliomas and pulmonary chondromas [1]. GISTs
typically arise in the stomach and follow a prolonged and indolent
course in patients with Carney’s triad. Patients with von Reckling-
hausen’s disease, or neuroﬁbromatosis type-1 (NF-1), have a predis-
position for GIST, but more commonly develop gliomas and
neuroﬁbromas as part of the NF-1 syndrome. The development of
GIST in NF-1 is thought to be due to a loss of the gene encoding
neuroﬁbromin that predisposes the interstitial cells of Cajal to hyper-
plasia [11]. GISTs associated with NF-1 may also be more indolent
and less aggressive than sporadic GISTs [12] and are typically found
in the small bowel. Familial GISTs are part of a syndrome with
germline mutations in c-kit or pdgfr-a, and are found to be associ-
ated with cutaneous hyperpigmentation, primarily on the hands and
perineum, and other gastrointestinal problems such as dysphagia,
irritable bowel syndrome, diverticular disease, and others [13]. These
patients usually present with multiple primaries, and again the dis-
ease is often more indolent than sporadic GISTs [1]. Carney-Strata-
kis syndrome is another inherited germline disorder that involves a
dyad of the tumors seen in Carney’s triad. Patients with GIST in the
setting of this syndrome typically are diagnosed with disease in
the stomach. Even though GIST arising in a non-familial GIST
syndrome usually expresses the C-KIT protein, c-kit and pdgfr-a
genes are unmutated, and patients who develop GIST in this setting
have a lower likelihood of tumor responding to kinase inhibitors tar-
geting activated C-KIT and PDGFR proteins.
RISK STRATIFICATION
For patients initially diagnosed with primary GIST without evi-
dence of metastases, tumor location, size, and mitotic rate have been
found to be associated with a higher risk for recurrence and the
development of metastases after surgical resection [14]. These three
predominant factors were used to develop risk stratiﬁcation by a
National Cancer Institute consensus conference and subsequently a
prognostic nomogram by Gold, et al., with the purpose of providing
guidance for selecting patients who may potentially beneﬁt from
adjuvant treatment after primary resection. Tumor size >10 cm,
mitotic index >5 per 50 high-power ﬁelds (HPF) of view and small
intestine as the site of origin were associated with the highest prob-
ability for recurrence, while tumor size <5 cm, mitotic index <5 per
50 HPF and stomach as the site of origin were associated with the
lowest probability for recurrence using a point system that predicted
2 and 5 year progression-free survival [14]. The use of adjuvant
therapy for high-risk GIST following resection will be discussed in a
different section, though understanding which aspects of this disease
portend a poorer prognosis can be helpful in appreciating the devel-
opment of advanced disease.
THERAPY FOR ADVANCED GIST
Molecular targeted therapies have become important and exciting
in the treatment of cancers for which speciﬁc mutations thought to
be crucial for pathogenesis have been discovered. However, prior to
the discovery of these pathologically important mutations and the
development of targeted therapy directed at these mutated proteins,
drug therapy for advanced GIST was non-speciﬁc and disappoint-
ingly ineffective. Here, we review a few of the chemotherapies
studied in advanced GIST for historical perspective.
Historical Perspective
Systemic chemotherapy given as either single agent or as a com-
bination of agents that are known to be of beneﬁt in other sarcomas
such as leiomyosarcoma have been mostly inactive in patients with
GIST. One study from Mayo Clinic published in 1999 evaluated the
response to dacarbazine, mitomycin C, doxorubicin, cisplatin, and
growth factor support in patients with GIST or leiomyosarcoma and
reported that one out of 21 patients with GIST had a partial response
(4.8%) compared to 67% of patients with leiomyosarcomas [15].
DeMatteo, et al. [16] reviewed a series of trials evaluating different
combinations of chemotherapeutic drugs such as doxorubicin, dacar-
bazine, ifosfamide, cisplatin, and others to treat patients with
advanced GISTs and reported partial responses of between 0 and
15% among a total of 266 patients, with a mean partial response rate
of 8.3%. Therefore, traditional cytotoxic chemotherapy has poor
activity against GIST providing increased motivation for the devel-
opment of novel agents.
Intraperitoneal (IP) chemotherapy for the treatment of GIST was
proposed initially by Berthet, et al. [17] in order to reduce peritoneal
recurrence after surgical resection of GIST and other intra-abdominal
sarcomas. Because GISTs tend to spread to serosal surfaces by
regional metastasis, this strategy was thought to be promising. Inves-
tigators have used IP instillation of cisplatin with doxorubicin or
single-agent mitoxantrone in an effort to limit systemic toxicity and
control peritoneal disease. Eilber et al. [18] looked speciﬁcally at IP
mitoxantrone in 33 patients with recurrent GIST with either limited
peritoneal involvement, or peritoneal and liver involvement. All
patients underwent surgical resection of all gross disease in the
abdomen and those with liver involvement underwent treatment
(resection, chemoembolization, or cryotherapy) of the liver lesions.
All 33 patients received 4–6 cycles of IP mitoxantrone. The 33
patients were compared to 13 patients who only had surgery without
IP chemotherapy. Among the patients treated with surgery alone, dis-
ease recurred in all 13 and only 23% were alive at a mean follow-up
time of 19 months. Among the patients treated by surgical resection
followed by IP therapy, disease recurred in 85% of patients at a
median of 11 months, however the other 15% were disease free at a
mean follow-up of 39 months, and 27% were alive at a mean follow-
up of 43 months. This small, non-randomized study suggests that a
small proportion of carefully selected patients may have long-term
beneﬁt from IP chemotherapy following surgical resection. However,
in the era of available tyrosine kinase inhibitor therapy, treatment of
GIST with chemotherapy has been supplanted.
Radiation therapy has been found to have limited capacity to
affect GISTs and isn’t routinely used for advanced disease because
metastases usually affect more than one area. Sometimes radiation
can be used for palliation of a bulky tumor if it causes pain or to
control bleeding. However, literature using this method of control is
limited; radiation has an unknown beneﬁt in advanced GIST outside
of palliating symptoms [16].
Imatinib Use in GIST
Imatinib is a small molecule tyrosine kinase inhibitor that was
developed in the mid-1990s based on its ability to inhibit the ABL
and BCR/ABL tyrosine kinases. It was ﬁrst approved for treatment
of the hematologic disorder chronic myelogenous leukemia because
of the drugs remarkable efﬁcacy. Imatinib was also found to inhibit
the transmembrane tyrosine kinase receptors C-KIT and PDGFR
alpha and beta. In 1998, Hirota, et al. [19] discovered that some
patients with GISTs had mutations in the C-KIT tyrosine kinase that
aberrantly activated the kinase in tumor tissue. Since the discovery
of these activating mutations in GISTs, it was hypothesized that
aberrant tyrosine kinase activity may be an important etiologic factor
in the development of GIST. Investigation of the impact of therapy
speciﬁcally inhibiting the tyrosine kinase activity in GIST has been
rapid in development considering the limited efﬁcacy of other
systemic therapy. In 2000, Joensuu, et al. [20] used imatinib to treat
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advanced GIST in a single patient with widely metastatic disease.
This single patient achieved a major objective disease response
detected by magnetic resonance imaging and positron emission tom-
ography that persisted for more than 18 months. After 4 weeks, biop-
sies of GIST metastasis in this patient revealed a histology of mostly
myxoid degeneration and ﬁbrosis, suggesting induced apoptosis
caused by imatinib. Because of the success seen in this patient, and
the desperation in the medical community to discover an active treat-
ment for metastatic GIST, subsequent large-scale studies using imati-
nib were developed and completed shortly thereafter.
Treatment of Advanced/Metastatic Disease
Blanke, et al. [3] conducted a prospective, randomized, phase II
trial (B2222) of patients with advanced GIST assigned to receive
either 400 mg or 600 mg daily of imatinib. Patients who showed
tumor response to imatinib were offered participation in an extension
trial that followed them for four more years on daily imatinib.
Patients (147) were initially enrolled in the core study with
67 patients completing the study. Fifty-six of the 67 patients com-
pleting the core study were entered into the extension study. Out of
the initial 147 patients enrolled, 68.1% of patients achieved a partial
or complete response, with an additional 15.6% of patients maintain-
ing stable disease without progression over a follow-up of up to
71 months.
After impressive results were seen with imatinib in the random-
ized phase II study, subsequent larger scale conﬁrmatory trials were
done to evaluate response and toxicity rates. In a trial by Verweij
et al. [21] comparing 400 mg versus 800 mg of imatinib daily in
patients with metastatic GIST, 946 patients were enrolled, random-
ized and followed on an intent-to-treat basis with cross-over allowed
from the lower to higher dose treatment following progression of
disease. Over a median follow-up of 760 days, there were no signiﬁ-
cant differences between the groups in rates of objective response,
stable disease, or tumor progression. Fifty percent of the patients in
the 400 mg group had a partial or complete response, compared with
54% of patients in the 800 mg group. Thirty-two percent of patients
in the 400 mg and 800 mg group had stable disease, and 13% of
patients in the 400 mg group compared with 9% of patients in the
800 mg group had tumor progression. A phase III study performed
in North America (S0033) that was published in 2008 also compared
400 mg versus 800 mg daily dosing of imatinib in 746 patients and
found similar results to the contemporaneous European Organization
for Research and Treatment of Cancer (EORTC) trial for objective
response, stable disease, and progression [22]. This phase III trial
also looked at progression-free survival and overall survival between
the two groups and found no statistically signiﬁcant difference. How-
ever, there was a difference in toxicity, with reported higher rates of
grade 3, 4, and 5 toxicities in the 800 mg group. Therefore, the con-
clusion of the study was that 400 mg daily dosing is an appropriate
starting dose for patients with metastatic GIST, with less risk for
toxicity than the higher starting dose [22]. The Food and Drug
Administration approved the marketing of imatinib at a starting dose
of 400 mg daily for treatment of patients with advanced or relapsed
GIST.
In patients whose disease progressed on imatinib 400 mg daily,
cross-over was allowed to the 800 mg dose in S0033 and 31% of
the patients who crossed over had stabilization of disease growth
with a median gain in progression free survival of 5 months follow-
ing cross-over [22]. Because of a reasonable chance for tumor con-
trol following increase in imatinib dose, the Soft Tissue Sarcoma
Guideline Panel from the NCCN recommended dose escalation to
800 mg a day in patients whose disease has progressed on the
400 mg daily dose as long as side effects from imatinib are easily
manageable [23].
Neoadjuvant Imatinib Therapy for
Locally Advanced Disease
Because imatinib has been shown to be effective against meta-
static GIST, naturally investigators evaluated its use in the adjuvant
and neoadjuvant setting in an attempt to increase cure rates. A few
trials have investigated the perioperative use of imatinib in poten-
tially resectable localized or metastatic disease to demonstrate its
safety. However, these trials did not speciﬁcally evaluate the effect
of pre-operative imatinib on surgical margin outcomes nor demon-
strate a signiﬁcant survival beneﬁt from pre-operative imatinib
because all patients received post-operative imatinib for 2 years
[24,25]. Another hypothesis that was evaluated is that patients with
marginally resectable disease, or tumors in locations that pose a high
surgical morbidity, would beneﬁt from neoadjuvant (pre-operative)
use of imatinib. A retrospective study of 46 patients with locally
advanced, recurrent, or metastatic disease demonstrated that neoadju-
vant imatinib improved some of the patients’ chances for complete
resection [26]. The duration of pre-operative imatinib varied by
patient, depending on disease response on serial imaging tests.
Patients were taken to surgery when their every 2–3 month computed
tomography scan ceased to show further reduction in tumor size or
showed progression of disease. Eleven of the 46 patients were treated
with imatinib for a median of 11.9 months for locally advanced
GIST prior to resection of disease. At a follow-up of 19.5 months,
all 11 were living and 10 were free of disease. Of the 46 patients,
those who experienced a partial tumor response to imatinib had a
greater chance for complete resection (91% vs. 4%, P < 0.001).
A prospective study performed by Hohenberger, et al. [27] in
36 patients with locally advanced or recurrent GISTs evaluated pre-
operative GIST response to imatinib, the extent of surgery required
for tumor excision, morbidity of surgery and local disease recurrence
rates. Median tumor shrinkage of about 5 cm was seen (from a
median of 10.5 cm pre-imatinib to 5.5 cm immediately pre-op) in
33 patients who underwent a median of 11 months of pre-operative
imatinib therapy. Twenty-eight of the 33 patients had complete resec-
tion of tumor, and in 83% the previously ‘‘inoperable’’ disease
became operable after neoadjuvant therapy. In regards to morbidity,
21 of 25 patients underwent less morbid surgeries due to tumor
response from the neoadjuvant therapy.
Imatinib has not been approved for pre-operative treatment in
patients with resectable, localized GIST. However, as imatinib is
now occasionally used neoadjuvantly, there have been reports of
potentially deleterious effects in some patients treated pre-opera-
tively. The dramatic tumor shrinkage that can occur with imatinib
may put some patients at increased risk of severe gastrointestinal or
IP bleeding, such as in patients with rare duodenal GISTs [28]. How-
ever, patients with large tumors in the stomach may have a decreased
risk of intra-operative tumor rupture and easier resection following
neoadjuvant imatinib [29]. Therefore, the decision for or against neo-
adjuvant use of imatinib should be made in a multi-disciplinary set-
ting in order to individualize therapy for each patient’s unique tumor
anatomy. With good pre-operative response to imatinib, tumors in
areas such as the rectum or gastroesophageal junction, that would
otherwise require a highly morbid surgery, may be amendable to
sphincter- and esophagus-sparing surgeries, respectively.
Dosing of Imatinib
Whether measurement of imatinib serum levels will be helpful in
assessing dose adequacy in patients treated for GIST is controversial.
A sub-group of 73 patients from the B2222 study had imatinib
levels drawn on days 1 and 29 after beginning either 400 or 800 mg
of imatinib daily. In a retrospective analysis, in the group of patients
who had a level <1,100 ng/ml, the time to progression was
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11.3 months as compared to a time to progression of greater than
30 months in the group of patients with a level >1,100 ng/ml [30].
There is an ongoing, randomized, prospective trial examining
whether an increase in dose for patients found to have imatinib levels
<1,100 ng/ml will affect outcomes. However, due to the lack of
evidence that increasing imatinib dose in patients based on drug
levels in serum will alter risk of disease progression, measuring ima-
tinib levels is not recommended.
Duration of Imatinib Therapy
The duration of imatinib therapy in metastatic GIST has been
evaluated in a French Sarcoma Group study randomizing patients
with responding or stable disease to interruption of treatment after
1 year and after 3 years of imatinib [31,32]. Out of 182 patients
initially enrolled in the trial, 58 of the patients who experienced
tumor control for at least 1 year were randomized to treatment inter-
ruption or continuation of imatininb. Ninety-one percent of the
patients in the treatment interruption arm experienced tumor pro-
gression with a mean progression-free survival of 6 months from
stopping imatinib compared to a 29-month progression-free survival
in the arm that continued imatinib. However, there was no difference
in overall survival between the two groups since the majority (86%)
of patients who progressed after drug interruption achieved disease
control after re-starting imatinib. The same end-points were then
evaluated with interruption of imatinib after 3 years. Out of
378 patients with metastatic GIST enrolled in the study, 50 were
eligible for randomization after 3 years. The 1-year progression-free
survival rate was 92% in the arm that continued imatinib versus
29.7% in the arm that had interruption of their treatment. Again,
there was no difference in overall survival since all patients in the
interruption arm were able to re-gain control of their disease after re-
starting imatinib. Based on the results of this study, continuation of
imatinib for treatment of metastatic GIST is recommended even fol-
lowing complete tumor response to therapy. A brief period without
imatinib therapy, for example to allow for elective surgery, does not
seem to increase risk of tumor resistance to imatinib.
Metabolism of Imatinib
Imatinib is metabolized through the hepatic p450 enzyme system
by CYP3A4, which is an enzyme central in the metabolism of other
medications such as the azoles, rifampin, phenytoin, and warfarin.
Inhibitors of CYP3A4 enyzyme activity, such as ketaconazole and
grapefruit juice can increase imatinib levels in the serum and
possibly cause increased toxicity of imatinib at normal treatment
doses. Rifampin and phenytoin are two medications that are known
to induce activity of the CYP3A4 enyzme and therefore may lead to
rapid metabolism of imatinib reducing efﬁcacy at normal treatment
doses [1]. Therefore, care should be taken when prescribing imatinib
along with other medications known to affect CYP3A4 activity.
Adverse Effects of Imatinib
Adverse effects of imatinib that can ensue in most patients are
typically tolerable at 400 mg daily dose. Diarrhea, ﬂuid retention,
nausea, fatigue, muscle cramps, abdominal pain, and rash are the
most common associated side effects of imatinib [33]. Gastrointesti-
nal upset caused by imatinib can sometimes be prevented by taking
the drug with food, though supportive medications such as proton-
pump inhibitors and loperamide for dyspepsia and diarrhea, respect-
ively, can be helpful as well. Fluid retention is a bothersome symp-
tom for many patients, commonly involving the lower extremities
and periorbital area, though it can rarely be severe enough to cause
ascites and pleural and pericardial effusions. Signiﬁcant edema can
be managed with sodium restriction and furosemide. Muscle cramp-
ing is also a particularly annoying adverse effect that is treated by
increasing ﬂuid intake, electrolyte replacement beverages, tonic
water, and muscle relaxants [1]. Some patients with large bulky
tumors, especially duodenal GISTs may have an increased risk for
hemorrhage and therefore hemoglobin in these patients should be
closely monitored. Myelosuppression and elevated transaminases are
less common, and usually resolve with temporary discontinuation of
therapy [33]. If leukopenia or severe neutropenia occurs, the current
guidelines recommend holding imatinib until blood counts recover
the then re-initiating therapy at the former dose [1]. Anemia that
develops in patients on long-term imatinib therapy can be caused by
iron deﬁciency, B12 deﬁciency, folate deﬁciency, and suppression of
hematopoiesis by imatinib [1]. Rarely, severe adverse effects such as
acute myelogenous leukemia (AML) and congestive heart failure
(CHF) have been reported [34,35]. Discontinuation of therapy in the
setting of severe adverse events such as AML and CHF is warranted
along with initiation of treatment for these respective conditions.
Resistance to Imatinib
Imatinib mesylate is a selective inhibitor of a number of tyrosine
kinsases, including ABL, BCR/ABL, KIT, and PDGFR. C-KIT is the
most commonly mutated tyrosine kinase seen in GIST, and therefore
inhibiting C-KIT activity to control the growth of GIST is an import-
ant goal of treatment. A subset of GISTs that do not harbor a
mutation in c-kit typically have either pdgfr-a activating mutations
or are considered ‘‘wild-type’’ GISTs with no identiﬁable mutations
in these genes. Mutations in c-kit and pdgfr-a appear to be mutually
exclusive in that the presence of mutant c-kit excludes mutation in
pdgfr-a in the same tumor and vice versa. There are different types
(point mutations, deletions, insertions) and locations of mutations
within the c-kit and pdgfr-a genes; mutations in exons 11 and 9 of
c-kit comprise approximately 70% and 15%, respectively, of primary
mutations in GISTs [7,36]. Mutations in c-kit exons 13 or 17 are
much less common. A small proportion of activating mutations seen
in GISTs are in exon 12 or 18 of the pdgfr-a gene (between 2
and 5%) [37,38]. About 10% of GISTs are typically denoted as
‘‘wild-type’’ since no readily identiﬁable activating mutation in the
transmembrane receptor kinase c-kit or pdgfr-a genes are found.
Among the activating mutations in exon 11 of c-kit, the most
common mutation observed was an in-frame deletion of a portion of
the juxtamembrane domain sometimes accompanied by an insertion
or a point mutation [7]. Most of the exon 11 mutations in c-kit occur
between codons 550 and 561 [39]. In exon 9 of c-kit, the activating
mutations seen have been in-frame duplications resulting in an inser-
tion, usually at codon 502 and infrequently at codon 506 [7]. The
most frequently observed activating mutations in pdgfr-a is a point
mutation in the kinase activation loop coded in exon 18 resulting in
an amino acid change at position 842 (D842V), and a point mutation
in the juxtamembrane domain coded in exon 12 (V561D) [7].
The responsiveness of GISTs to imatinib has been observed to
differ depending on which mutation is present. Thirty-seven tumor
specimens taken from patients being treated with imatinib in an
EORTC phase I or II trial were evaluated for mutations by extracting
DNA and using PCR to amplify the different areas of interest from
the c-kit and pdgfr-a genes. This study found that 50% of patients
with mutations in exon 11 of c-kit were free from disease pro-
gression at 104 weeks of therapy, compared to 25% of the patients
with c-kit exon 9 mutations, 0% of the patients with pdgfr-a
mutations and 33% of patients with ‘‘wild-type’’ GIST. The number
of samples in this study were small, though statistical signiﬁcance
for improved progression-free survival with a P-value of 0.03 was
observed for patients carrying c-kit mutations compared to all other
patients. Another study by Heinrich, et al. [37] evaluated the GIST
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genotypes from patients treated in the phase III SWOG S0033 trial.
They observed the median time to tumor progression for patients
with mutations in c-kit exon 11, c-kit exon 9, and ‘‘wild-type’’
GISTs to be 24.7, 16.7, and 12.8 months, respectively. Median over-
all survival was 60.0, 38.4, and 49.0 months for patients with c-kit
exon 11, exon 9, and ‘‘wild-type’’ GISTs, respectively. This study
did not detect a signiﬁcant difference in time to tumor progression or
overall survival for patients with c-kit exon 9 mutations treated with
400 mg versus 800 mg daily dose of imatinib, but a different study
by Debiec-Rychter, et al. [36] detected a statistically signiﬁcant
(P ¼ 0.0013) difference in progression-free survival in patients with
exon 9 mutations treated with 400 mg versus 800 mg daily dose of
imatinib with a relative risk reduction of 61% in patients who
received the 800 mg daily dose. Some pdgfr-a mutations are more
responsive to imatinib than others, such as mutations in exon 12 or
14 [40]; however the most common mutation in pdgfr-a is in exon
18 which is resistant to imatinib in in vitro studies [40].
Secondary imatinib resistance is a phenomenon of GIST pro-
gression after a period of tumor control [41]. Patients who have pro-
gression of disease within the ﬁrst 2 months of imatinib therapy are
thought to have primary imatinib resistance. Patients with disease
previously sensitive to imatinib who have evidence of disease pro-
gression may have outgrowth of tumor with secondary mutations in
either the c-kit or pdgfr-a or development of resistance through
different mechanisms. Gene ampliﬁcation of the activated tyrosine
kinase, loss altogether of C-KIT or PDGFR-A expression, interfer-
ence with imatinib binding to the adenosine-triphosphate (ATP)-
binding site in the kinase and increased clearance of imatinib are
some proposed mechanisms of secondary imatinib resistance [41].
Some of the mutations in c-kit associated with secondary resistance
were discovered through molecular genotyping of tumor samples and
in vitro modeling of sensitivity to kinase inhibition [38]. Mutations
in exon 13 or 14 that encode the ATP binding pocket of C-KIT are
the most frequently observed secondary mutations; the V654A
mutation in exon 13 is a common secondary mutation. Mutations in
exon 17 that encodes the activation loop of C-KIT have been seen as
well [38]. Interestingly, a study performed by Heinrich, et al. [38]
observed secondary mutations more commonly in GISTs that had a
primary exon 11 c-kit mutation compared to tumors that had a
primary exon 9 c-kit mutation (73% vs. 19% P ¼ 0.0003). In the
same study, there were only four patients with primary pdgfr-a
mutations, one of which had a primary exon 12 mutation and a sec-
ondary exon 18 mutation. Not surprisingly, the GISTs with primary
exon 18 mutations did not develop secondary mutations, supporting
in vitro studies that GISTs with pdgfr-a exon 18 mutations are prim-
arily resistant to imatinib. Patients found to have secondary resist-
ance to imatinib may be managed by increasing the dose of imatinib
(if not previously done), switched to second-line treatment using
sunitinib or enrolled in a clinical trial.
Sunitinib Use in GIST
Sunitinib malate is a direct inhibitor of C-KIT, PDGFR, vascular
endothelial growth factor (VEGF)-1, VEGF-2, VEGF-3, Fms-like
tyrosine kinase-3 (FLT3), and the receptor encoded by proto-onogene
ret. Sunitinib is currently approved for use in advanced GIST that is
imatinib resistant or in patients with advanced GIST who are not
able to tolerate imatinib. A multi-center phase III trial evaluating
sunitinib for these indications enrolled 312 patients with advanced
GIST between 2003 and 2005 who were previously on imatinib and
either could not tolerate the medication or in which disease pro-
gressed [42]. Two-hundred and seven patients were randomized to
receive sunitinib 50 mg daily for 4 weeks followed by a 2-week
break per cycle of treatment, and 105 patients received placebo. The
trial was unblinded early due to an interim analysis revealing a
dramatic effect of sunitinib versus placebo in patients after two
cycles. Median time to tumor progression was 26 weeks in patients
receiving sunitinib and 6 weeks in the placebo group. Even though
cross-over from placebo to sunitinib was allowed upon progression,
overall survival was better in the group initially assigned to sunitinib
(hazard ratio (HR) 0.49, P ¼ 0.007), though the median survival had
not yet been reached since the majority of the patients in the suniti-
nib group were living at the time of interim analysis.
Dosing of Sunitinib
The currently approved dose for sunitinib as second-line therapy
in advanced GIST is a 6-week cycle with 50 mg daily for 4 weeks
followed by 2 weeks off (4/2 schedule). A phase II study recently
evaluated whether continuous daily dosing at a lower dose of
37.5 mg daily would be potentially as efﬁcacious and less toxic than
the 4/2 schedule [43]. The median progression-free survival was
34 weeks and the median overall survival at the time of analysis was
107 weeks, which the authors noted to be comparable to the phase
III study reported by Demetri, et al. However, the phase II study of
continuous daily dosing of sunitinib was not a randomized compara-
tive trial. The adverse effects reported in the study evaluating the 4/2
schedule and the study evaluating continuous daily dosing were com-
parable. Further discussion of adverse effects of sunitinib will be dis-
cussed below. Due to the similar efﬁcacy and adverse effect proﬁle,
the authors concluded that the continuous daily dosing could be seen
as an acceptable alternative to the currently recommended 4/2 sched-
ule, though the study was not designed to evaluate equivalence or
superiority compared to the approved dose and schedule.
Metabolism of Sunitinib
Like imatinib, sunitinib is also metabolized by the CYP3A4
enzyme, and therefore potential drug interactions that could increase
or decrease the serum levels of this medication are the same as those
seen with imatinib. One speciﬁc recommendation noted in the NCCN
guidelines addresses the concurrent administration of sunitinib with
a medication that induces the CYP3A4 enzyme, thereby lowering
the serum concentration of sunitinib. In this situation, the dose of
sunitinib can be titrated to a maximum of 87.5 mg in the 4 weeks
on, 2 weeks off schedule as long as patients are carefully monitored
for toxicities [1].
Adverse Effects of Sunitinib
Adverse events associated with sunitinib are relatively common,
but usually are only mild to moderate. Fatigue, diarrhea, and skin
discoloration were the most common non-hematologic adverse
events seen in the phase III study comparing sunitinib to placebo,
with the majority of these being grades 1–2 [42]. Nausea, decreased
appetite, hand-foot syndrome, and rash were also seen in more than
10% of patients, though again mostly at grade 1 or 2 [42]. In the
study evaluating continuous daily dosing, diarrhea, fatigue, hyperten-
sion, and nausea were the most common adverse events [43]. Ane-
mia and neutropenia are common hematologic adverse events seen
in both 4/2 schedule and the continuous daily schedule [42,43].
However, in the trial comparing sunitinib to placebo, anemia
occurred in 62% of patients receiving sunitinib compared to 60% of
patients receiving placebo, illustrating that some adverse effects
associated with treatment are due to tumor burden [42]. Neutropenia,
on the other hand, was seen in 51% of patients who received suniti-
nib and only 4% of patients who received placebo [42]. Hyperten-
sion is a side effect that has been typically seen in patients receiving
sunitinib for renal cell carcinoma, but is less commonly seen in
patients receiving sunitinib for GIST, despite similar dosing [44]. A
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study evaluating the toxicities of sunitinib in patients with renal cell
carcinoma versus non-renal cell carcinoma patients revealed a 25.9%
incidence of any grade hypertension in renal cell patients versus a
19.6% incidence in patients on sunitinib for other reasons. This dis-
crepancy may be related to involvement of the kidney in renal cell
carcinoma or prior nephrectomy that may predispose patients to hy-
pertension. CHF is another more serious adverse event that has been
found to occur in association with sunitinib. In the Phase I/II studies
of sunitinib, CHF was detected in 8% of 75 patients evaluated.
Almost 50% of 32 patients who received the approved dose of suni-
tinib had a decrease in their ejection fraction by at least 10% [45].
Hypothyroidism has recently been reported as well; a prospective,
observational cohort study detected an abnormal thyroid stimulating
hormone (TSH) level in 62% of patients on suninitb [46]. Therefore,
the NCCN task force recommends following TSH levels every 3–
6 months as long as patients are being treated with sunitinib [1].
Resistance to Sunitinib
Sunitinib malate is a small-molecule tyrosine kinase inhibitor,
similar to imatinib, though selective for KIT, PDGFRA, PDGFRB,
all three isoforms of VEGFR, FLT3, CSF-1R, and RET. Sunitinib
has been shown to be effective against certain mutations in GISTs
that are resistant to imatinib, whether through primary or secondary
resistance.
A continuation trial of sunitinib in 97 patients with metastatic
imatinib-resistant or imatinib-intolerant GIST assessed the mutational
status in 78 tumor specimens from enrolled patients [38]. After
6 months, partial response or stable disease rate observed in patients
with primary mutations in c-kit exon 9, c-kit exon 11, and wild-type
c-kit/pdgfr tumors was 58%, 34%, and 56%, respectively. No clinical
beneﬁt (deﬁned as partial response or stable disease) was observed
for the four patients with mutations in pdgfr-a. Progression-free sur-
vival and overall survival were signiﬁcantly longer for patients with
primary c-kit exon 9 mutations and wild-type tumors compared to
those with c-kit exon 11 mutations. Median overall survival in
patients with an exon 9 mutation or a wild-type tumor was
26.9 months (P ¼ 0.12) and 30.5 months (P ¼ 0.132), compared to
only 12.3 months in patients with an exon 11 mutation. The fact that
sunitinib was more effective in tumors with exon 9 mutations com-
pared to those with exon 11 mutations is not an indication that exon
11 mutant GIST is resistant to sunitinib, but is a testament that sec-
ondary mutations in primary c-kit exon 11 mutated GIST leading to
imatinib resistance also confer resistance to sunitinib. Median pro-
gression-free survival in patients with secondary c-kit mutations
receiving sunitinib was signiﬁcantly longer in those with a mutation
in exon 13 or 14 of c-kit as compared to those patients with an exon
17 or 18 c-kit mutation (7.8 months vs. 2.3 months, P ¼ 0.0157).
In vitro analyses were done on cell lines from 78 tumor speci-
mens from the studied patients to evaluate the potency of sunitinib
against certain mutations [38]. Sunitinib was found to be potent in
inhibiting the activity of the receptor in ‘‘wild-type’’ tumors and in
tumors containing c-kit exon 11 V560D or exon 9 mutations. Tumors
with c-kit double mutants (those tumors that developed secondary
mutations) with the second mutation in the drug/ATP binding site of
the receptor (exons 13 and 14) were potently inhibited by sunitinib,
but tumors with secondary mutations observed in the activation loop
(exons 17 and 18) were resistant to sunitinib. Sunitinib was also
found to be effective at inhibiting phosphorylation (activation) of
wild-type PDGFR-A or PDGFR-A with the V561D mutation. How-
ever, the most common PDGFR-A mutation in GIST, the D842V
mutation in exon 18, showed resistance to sunitinib.
A randomized trial of sunitinib versus imatinib as ﬁrst-line treat-
ment in patients with primary mutation in exon 9 of c-kit or with
wild-type GIST has not been performed and would be difﬁcult to
complete because of the infrequency of primary c-kit exon 9 mutant
GIST. However, the study reported by Heinrich, et al. [38] that eval-
uated in vitro activity of sunitinib and imatinib in tumors with differ-
ent activating mutations demonstrated that sunitinib was more potent
than imatinib in inhibiting growth of some of the GISTs harboring
mutations in exon 9 of c-kit. Further study needs to be done to deter-
mine whether mutational analysis should be an important ﬁrst step in
determining the best treatment for patients diagnosed with advanced
GIST. Currently, imatinib is the ﬁrst-line agent for all patients diag-
nosed with advanced or metastatic GIST regardless of tumor muta-
tional status, but an interesting question to investigate would be
whether newly diagnosed patients with potentially imatinib-resistant
mutations would beneﬁt from ﬁrst-line treatment using sunitinib or
another tyrosine-kinase inhibitor.
CONCLUSION
Approximately 4,000–6,000 patients are diagnosed with GIST in
the US yearly and less than one-half have advanced unresectable
tumors or metastasis. For patients with localized, resectable GIST,
complete resection is curative in the majority but risk stratiﬁcation
schemes provide important prognostic information. Prior to the intro-
duction of small molecule tyrosine kinase inhibitor therapy,
advanced or metastatic GIST was a rapidly fatal disease. Following
the development of tyrosine-kinase inhibitor therapy, this rare but
lethal sarcoma has become manageable and even a chronic condition
in many patients. Imatinib 400 mg daily is the recommended treat-
ment for patients with unresectable or metastatic GIST with an
expected tumor response rate of about 50%, stable disease rate of
about 35% and primary refractory disease to imatinib in about 15%
of patients. In patients with tumor progression on 400 mg daily of
imatinib, control of disease may be achieved in about one-third of
patients after increasing the dose to a total of 600–800 mg daily.
This maneuver seems to be more likely to control tumors that do not
harbor a primary mutation in exon 11 of c-kit. Sunitinib is effective
in the treatment of GIST and is approved for use after failure of or
intolerance to imatinib. Many of the patients with advanced GIST
treated with imatinib and/or sunitinib will develop drug-resistant
tumors and are in desperate need of alternative treatments. As we
learn more about the mutations associated with the pathogenesis of
GIST, including the secondary mutations that develop while on ﬁrst-
line imatinib therapy or secondary therapy with sunitinib, with fur-
ther reﬁnement of the techniques to genotype GIST biopsies and
development of small molecules to overcome the effects of secon-
dary mutations in kinases, future therapy may be tailored to the indi-
vidual patient based on mutational proﬁle of the GIST. A realistic
hope is that patients and clinicians will see advanced GIST turned
from a fatal cancer into a long-term chronic disease.
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